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Abstract
 .The key role of tetrahydrobiopterin BH4 in the synthesis of nitric oxide by human umbilical vein endothelial cells
 .  .HUVEC has been demonstrated. We characterized the induction of BH4 synthesis in a cell line ECV derived from
 .HUVEC and primary HUVEC. A significant induction of guanosine triphosphate cyclohydrolase I GTPCH mRNA was
observed in response to TNF, IL-1b , and IFNg in ECV and HUVEC. The induction of GTPCH mRNA was abolished by
actinomycin D. The cytokines led to an increased accumulation of BH4 in ECV. This effect was prevented by
2,4-diamino-6-hydroxypyrimidine, a selective inhibitor of GTPCH, as well as by actinomycin D and by cycloheximide.
Results provide evidence for an increase in GTPCH activity and in BH4 levels in response to immunostimulants in human
endothelial cells. q 1997 Elsevier Science B.V.
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1. Introduction
 .Tetrahydrobiopterin BH4 , the natural cofactor of
the three aromatic amino acid hydroxylases, is an
important regulatory factor in the biosynthesis of
such neurotransmitters as dopamine, norepinephrine,
w xand serotonin 1,2 . High levels of BH4 are present in
w xtissues that contain enzymes requiring BH4 3 . BH4
also serves as a cofactor of O-alkylglycerolipid cleav-
w xage enzyme 4 . BH4 is reportedly a cofactor for the
 .isoforms of nitric oxide synthase NOS and is re-
w xquired for catalytic activity 5 . An interference with
the synthesis or utilization of BH4 provides a poten-
tial means of selectively blocking the synthesis of
) Corresponding author. Fax: q81 282 864632.
 . w xnitric oxide NO 6,7 . Although significant basal
levels of BH4 have been found in limited types of
cells e.g. neuronal, adrenal, hepatic, and certain
.immune cells , the synthesis of BH4 can be induced
in a wide variety of additional types of cells by
w xexposure to immunostimulants 8 .
Vascular endothelial cells contain a distinct consti-
tutive Ca2qrcalmodulin-dependent NOS isoform
 . w x 2qecNOS 9–11 . ecNOS is activated by Ca influx
w xagonists and by the shear stress of blood flow 12 .
The NO formed following ecNOS activation is im-
portant in blood pressure homeostasis and in the
w xcontrol of organ perfusion 13–15 . Once the en-
dothelium has been exposed to inflammatory condi-
tions that produce such proinflammatory cytokines as
TNF, IL-1b , and IFN-g , the endothelial production
of NO appears to increase in the presence of a
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w xdecline in total NOS enzyme 16,17 . Cytokines in-
crease the specific activity of the ecNOS isoform via
w xelevation of the limiting cofactor BH4 17 .
BH4 is synthesized de novo from guanosine
 .triphosphate GTP by the sequential action of three
 .enzymes, GTP cyclohydrolase I GTPCH , 6-
pyruvoyltetrahydrobiopterin synthase, and sepiapterin
reductase. GTPCH is the first and rate-limiting en-
w xzyme 18 . We showed previously that an increase in
the amount of BH4 produced due to cytokine action
is required for the prolonged synthesis of NO by an
 .inducible isoform of NOS iNOS in rat vascular
w x smooth muscle cells 19 , rat cardiac myocytes un-
. w xpublished data , and human thyroid cells 20 in
which GTPCH induction accounts for the increase in
intracellular BH4 levels. Thus, a co-induction of
iNOS and GTPCH and, hence, of NO and BH4
synthesis have been demonstrated in these types of
cells. Cytokines have been shown to induce BH4
biosynthesis by increasing the activity of GTPCH in
w xhuman vascular endothelial cells 14,15 . However,
the regulation of BH4 production by cytokines in this
type of cell is not fully understood. The present study
evaluated the effects of cytokines on endothelial cells
obtained from human umbilical cord veins.
2. Materials and methods
2.1. Cell culture
ECV is a spontaneously transformed line of en-
dothelial cells that was established from the vein of
w xnormal human umbilical cord 21 . ECV were main-
tained by serial passage in medium 199 supplemented
with 10% fetal calf serum and antibiotics. Human
 .umbilical vein endothelial cells HUVEC at passage
level 3 or 4 were obtained from Kurabo Co. Osaka,
.Japan . HUVEC were used in these experiments after
they had grown to confluence in plastic culture dishes.
2.2. Biopterin assay
Total cellular biopterin tetrahydrobiopterin and
.more oxidized species was measured after the acidic
oxidation of the reduced forms of biopterin with
w xiodine, as previously described 3 . In brief, cells
 .were treated with 0.2 M perchloric acid PCA and
oxidized by exposure to 0.2 M PCA containing 0.2%
I and 0.4% KI for 1 h at room temperature in the2
 .dark. Ascorbate 2% was added to remove residual
free I and the mixture was centrifuged for 10 min at2
10 000=g. The amount of biopterin in the super-
natant was quantitated by C reversed-phase high-18
performance liquid chromatography with fluores-
cence detection using authentic biopterin as a stan-
dard. Protein concentration was measured by the
w xLowry method 22 , with bovine serum albumin as a
standard.
2.3. Analysis of NO synthase and GTP cyclohydro-
lase I mRNA abundance
RNA was extracted from ECV and HUVEC by a
modified guanidinium isothiocyanate method
 .RNAzol; CinnarBiotecx, Houston, TX, USA . Re-
verse transcription-polymerase chain reaction RT-
.PCR analysis was performed as previously described
w x19 . In brief, first-strand cDNA was synthesized
from random primers with murine Moloney leukemia
virus reverse transcriptase Promega, Madison, WI,
.USA and was then amplified by PCR with synthetic
gene-specific primers for human GTPCH. Primers
used were: GTPCH forward primer, 5X-CCGC-
CTACTCGTCCATCCTGA-3X; and GTPCH reverse
X X w xprimer, 5 -ACCTCGCATTACCATACACAT-3 20 .
PCR amplification was performed with a kit Perkin
.Elmer Cetus, Norwalk, CT, USA for 30 cycles of 30
s at 958C, 30 s at 558C, and 1 min at 728C. To ensure
that equal amounts of reverse-transcribed RNA were
added to the PCR, we subjected glyceraldehyde-3-
 .phosphate dehydrogenase GAPDH cDNA to am-
plification in parallel as a reference, with the primers
w xdescribed 23 . PCR products were separated by elec-
trophoresis on a 1.5% agarose gel containing ethid-
ium bromide and were visualized by ultraviolet
light-induced fluorescence. PCR resulted in a single
 .product of the predicted size for GTPCH 434 bp .
The identity of PCR products as those corresponding
w xto human GTPCH cDNA 24 was confirmed by
sequencing of the products by the dye terminator
method using the Applied Biosystems DNA Se-
quencer, model 373A Perkin-Elmer Applied Biosys-
.tems Division, Foster City, CA, USA .
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2.4. Materials
Human recombinant TNF was obtained from Gen-
 .zyme Cambridge, MA, USA . Human recombinant
IL-1b was a gift from Otsuka Pharmaceutical CO.
 .Tokushima, Japan . Human recombinant IFN-g was
a gift from Shionogi Pharmaceutical Co. Osaka,
.Japan . Other chemicals were purchased from Sigma
 .Chemical Co. St. Louis, MO, USA .
3. Results
Since BH4 synthesis is induced by immunostimu-
lants in various cell types including HUVEC, we first
examined whether cytokines regulated endogenous
levels of biopterin in ECV. Cellular biopterin levels,
 .which were low under basal conditions control ,
showed an increase after 24-h exposure to TNF 10
.  .  .ngrml or IL-1b 10 ngrml , but IFNg 100 Urml
 .had no effect Fig. 1 . The combination of TNF and
IL-1b , alone or together with IFN-g , further in-
 .creased the cellular biopterin levels in ECV Fig. 1 .
To determine whether the increase in cellular
biopterin induced by the combination of TNF, IL-1b ,
Fig. 1. Effect of cytokine combinations on cellular biopterin
levels in cultured ECV. Cells were isolated after 24 h of treat-
 .  . ment with TNF 10 ngrml , IL-1b 10 ngrml , and IFNg 100
.Urml . Biopterin was analyzed by HPLC after being oxidized by
iodine. Each bar represents the mean of two values, expressed as
biopterin per mg of cell protein.
 .  .Fig. 2. Effect of cycloheximide CHX , actinomycin D ACTD ,
 .and dexamethasone DEX on cellular biopterin levels in ECV.
 .Cells were treated with a combination of TNF 10 ngrml , IL-1b
 .  . 10 ngrml , and IFNg 100 Urml in the absence control:
.  .  .CONT and presence of CHX 1 mgrml , ACTD 0.5 mgrml ,
 .and DEX i mM for 24 h, after which cellular biopterin was
measured. Data are means of two experiments that yielded simi-
lar results, expressed as biopterin per mg of cell protein.
 .Fig. 3. Effect of 2,4-diamino-6-hydroxypyrimidine DAHP on
cellular biopterin levels in ECV. Cells were treated with a
 .  .combination of TNF 10 ngrml , IL-1b 10 ngrml , and IFNg
 .100 Urml in the presence of various concentrations of DAHP
for 24 h, after which cellular biopterin was measured. Data are
means of two experiments that yielded similar results, expressed
as biopterin per mg of cell protein.
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 .and IFNg TNFrIL-1brIFNg requires mRNA or
protein synthesis, experiments were performed with
actinomycin D and cycloheximide. Actinomycin D
 .  .0.5 mgrml and cycloheximide 1 mgrml both
Fig. 4. Time course of changes in mRNA levels for GTPCH and
 .  .effect of cycloheximide CHX , actinomycin D ACTD , and
 .dexamethasone DEX on the cytokine-induced increase in GT-
 .PCH mRNA abundance. A ECV were incubated with a combi-
 .  . nation of TNF 10 ngrml , IL-1b 10 ngrml , and IFNg 100
.  .Urml , and RNA was prepared at the times indicated. B ECV
 . and C HUVEC were incubated for 4 h in the absence control:
.CONT or presence of a combination of TNF, IL-1a , and IFNg
 .  .  .CYTrMIX alone or with CHX 1 mgrml , ACTD 0.5 mgrml ,
 .and DEX 1 mM , and RNA was prepared and assayed by
RT-PCR. Results with primers specific for GAPDH are shown
for comparison. DNA size markers in the left lanes correspond
to: 2000, 1200, 800, 400, and 200 bp.
 .reduced cellular biopterin to very low levels Fig. 2 .
This finding suggests that the increase in cellular
biopterin after TNFrIL-1brIFNg was due to the
induced production of biopterin. Dexamethasone had
no significant effect on cellular biopterin levels in
 .TNFrIL-1brIFNg-stimulated ECV Fig. 2 .
We next investigated whether the increase in intra-
cellular biopterin levels in TNFrIL-1brIFNg-
stimulated ECV was due to the de novo synthesis of
biopterin by using 2,4-diamino-6-hydroxypyrimidine
 .DAHP , a selective inhibitor of GTPCH. The
TNFrIL-1brIFNg-induced increase in cellular
biopterin was inhibited in a concentration-dependent
manner when cells were treated concomitantly with
 .  .DAHP 0.1–3 mM Fig. 3 .
To evaluate the basis for the increase in intra-
cellular biopterin, we investigated whether the cy-
tokines induce GTPCH mRNA in ECV. RT-PCR
with specific primers for GTPCH amplified a pre-
dicted 434-bp sequence corresponding to nucleotides
w x42-475 of human GTPCH cDNA 24 . Low levels of
GTPCH mRNA were detectable in untreated ECV.
Following treatment with TNFrIL-1brIFNg , levels
of GTPCH mRNA increased substantially within 4 h,
with high levels being sustained for at least 24 h Fig.
.4A . Fig. 4B shows the effects of cycloheximide,
actinomycin D, and dexamethasone on the induction
of GTPCH mRNA by the cytokines. Induction of
GTPCH mRNA by the cytokines was not signifi-
cantly reduced by dexamethasone or cycloheximide,
but was abolished by actinomycin D. Induction of
GTPCH mRNA in HUVEC was also characterized.
GTPCH mRNA in HUVEC is induced in response to
TNFrIL-1brIFNg . This induction was prevented by
 .actinomycin D Fig. 4C , as was observed in ECV.
Control PCR experiments demonstrated an equivalent
expression of the GAPDH gene in all samples Fig.
.4A,B,C .
4. Discussion
The present study investigated the effects of TNF,
IL-1b , and IFNg on the biosynthesis of biopterin in
ECV, a line of human endothelial cells. Treatment of
ECV with the combination of cytokines increased the
abundance of mRNA for GTPCH, the first and rate-
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limiting enzyme in the de novo synthesis of BH4,
resulting in the accumulation of BH4 in the cells.
DAHP, an inhibitor of GTPCH activity, reduced the
accumulation of BH4 caused by the combination of
cytokines. Cycloheximide and actinomycin D each
prevented the increase in cellular levels of biopterin
induced by the combination of cytokines. Results
indicate that biopterin synthesis requires mRNA and
protein synthesis and that the increase in cellular
biopterin after cytokine stimulation was due mainly
to the induced production of biopterin via a de novo
synthetic pathway, rather than via a salvage pathway
using pre-existing dihydropterins. The induction of
GTPCH mRNA in ECV stimulated with the combina-
tion of cytokines was abolished by actinomycin D but
was not significantly reduced by cycloheximide, sug-
gesting the synthesis of intermediary proteins is not
required for the induction of GTPCH mRNA. Thus,
GTPCH may be transcriptionally regulated, but these
data do not rule out the possibility that immunostimu-
lants act by prolonging the life time of GTPCH
mRNA. Since the 3X-untranslated region of the human
GTPCH mRNA contains multiple copies of a consen-
 .sus sequence AUUUA common to several early-re-
sponse genes and responsible for mRNA destabiliza-
w xtion 25–27 , regulation of mRNA stability could also
represent a site for the control of the expression of
GTPCH mRNA, as has been suggested in rat vascular
w xsmooth muscle cells 19 .
Previous reports by Werner-Felmayer et al. showed
that cytokines stimulate the biosynthesis of BH4 and
cGMP production in HUVEC by increasing activity
w xof the key enzyme GTPCH 16 . This suggests that
either the cytokine-induced synthesis of biopterin
arises from the post-translational activation of the
pre-existing GTPCH, or that GTPCH induction is
regulated by protein synthesis de novo. Our data
strongly support the latter possibility. More recently,
Rosenkranz-Weiss et al. demonstrated that inflamma-
tory cytokines selectively increase ecNOS activity in
w xHUVEC by increasing BH4 levels 17 . Interestingly,
it has been suggested by Cosentino and Katusic that
under conditions in which BH4 production is de-
creased, endothelial NOS from canine coronary arter-
ies may provide H O that leads to hydroxyl radical2 2
w xproduction and oxidative tissue damage 28 . Thus, a
close and important relationship between NO and
BH4 synthesis was demonstrated in endothelial cells.
Since ECV consists of spontaneously transformed
human endothelial cells, we questioned whether BH4
biosynthesis in ECV may be differently regulated by
cytokines than in the original endothelial cells, HU-
VEC. We found that GTPCH mRNA in ECV was
induced and regulated in the same way as in HU-
VEC. A decreased response in BH4 synthesis to
IFN-g was observed in ECV, which may be due to a
difference between HUVEC and ECV cells in the
w xexpression of the interferon receptor 29 . Thus, ECV
can be useful in studying the regulation and
metabolism of BH4 in human endothelial cells.
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